This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Clinical Experience With Carmustine (BCNU) and Vincristine

Derek Fewer, MD; Charles B. Wilson, MD; Edwin B. Boldrey, MD; K. Jean Enot, RN; Malcolm R. Powell, MD

JAMA. 1972;222(5):549-552.

Abstract
Eighty-one patients with recurrent primary or metastatic brain tumors were treated with carmustine (BCNU [1,3-Bis(2-chloroethyl)-1nitrosourea]) alone or carmustine and vincristine sulfate combined, and their responses analyzed. A response was defined as a clear clinical improvement unrelated to corticosteroid therapy. The overall response rate with carmustine was 48% and with the combination, 30%. In patients with glioblastoma, the response rates were 53% and 25%, respectively. The most responsive tumors were ependymomas; the least responsive, metastatic. The dose-limiting toxicity of carmustine was exclusively hematologic; of vincristine, exclusively neurologic, and severe enough to make drug effectiveness difficult to assess. We conclude that carmustine is an effective chemotherapeutic agent, with an acceptable level of toxicity, for the treatment of brain tumors. Vincristine did not enhance the effectiveness of carmustine and we have discontinued the use of these drugs in combination.

Author Affiliations
From the departments of neurological surgery and radiology, and the Cancer Research Institute, University of California School of Medicine, San Francisco.

Footnotes
Reprint requests to University of California School of Medicine, San Francisco 94122 (Dr. Wilson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Penetration of intra-arterially administered vincristine in experimental brain tumor
Boyle et al.
Neuro Oncol Duke 2004;6:300-306.
ABSTRACT  

Quality and Duration of Survival in Glioblastoma Multiforme: Combined Surgical, Radiation, and Lomustine Therapy
Hochberg et al.
JAMA 1979;241:1016-1018.
ABSTRACT  

Glioblastoma Multiforme
Weiss
Arch Neurol 1977;34:131-131.
ABSTRACT  

Glioblastoma Multiforme-Reply
Shapiro
Arch Neurol 1977;34:131-132.
ABSTRACT  

Single-Agent Chemotherapy of Brain Tumors: A Five-Year Review
Wilson et al.
Arch Neurol 1976;33:739-744.
ABSTRACT  

Treatment of Malignant Glioma: A Controlled Study of Chemotherapy and Irradiation
Shapiro and Young
Arch Neurol 1976;33:494-500.
ABSTRACT  

Chemotherapy of Childhood Medulloblastoma
Crist et al.
Arch Pediatr Adolesc Med 1976;130:639-642.
ABSTRACT